KLU156 + Coartem
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uncomplicated Plasmodium Falciparum Malaria
Conditions
Uncomplicated Plasmodium Falciparum Malaria
Trial Timeline
Mar 7, 2024 → Nov 25, 2025
NCT ID
NCT05842954About KLU156 + Coartem
KLU156 + Coartem is a phase 3 stage product being developed by Novartis for Uncomplicated Plasmodium Falciparum Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT05842954. Target conditions include Uncomplicated Plasmodium Falciparum Malaria.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05842954 | Phase 3 | Completed |
Competing Products
13 competing products in Uncomplicated Plasmodium Falciparum Malaria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZY19489 + Ferroquine (FQ) + Placebo | Zydus Lifesciences | Phase 1 | 33 |
| Artemether-lumefantrine (COA566) | Novartis | Phase 2/3 | 65 |
| INE963 | Novartis | Phase 2 | 52 |
| KAE609 + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation | Novartis | Phase 2 | 52 |
| INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + LUM-SDF + Coartem | Novartis | Phase 2 | 52 |
| Co-artemether | Novartis | Approved | 85 |
| Broncho-munal® + Placebo | Sandoz Group | Phase 3 | 74 |
| Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mg | Amneal Pharmaceuticals | Phase 3 | 72 |
| Peramivir + Placebo | BioCryst Pharmaceuticals | Phase 2 | 47 |
| solithromycin + ceftriaxone + azithromycin | Allergy Therapeutics | Phase 3 | 72 |
| Sulopenem-Etzadroxil/Probenecid + Ciprofloxacin | Iterum Therapeutics | Phase 3 | 69 |